ALK and non-small cell lung carcinoma: Two phase III studies, which led to the United State Food and Drug Administration (FDA) approval of crizotinib, further confirmed the superiority of crizotinib on standard chemotherapy as first or second line therapy of ALK-rearranged NSCLC patients [31, 32].